Source comparison
ARA-290 Side Effects Long Term Research: Adverse Events vs Placebo
Injection site reaction 10–15% 2–5% Transient erythema or mild induration at subcutaneous injection site, typically resolving within 24–48 hours Expected with any SC peptide. Not compound-specific Headache 6–8% 7–9% No dose-relationship observed; incidence ove
This comparison does not assign a generated winner or score.
- Injection site reaction
- 10–15%
- 2–5%
- Transient erythema or mild induration at subcutaneous injection site, typically resolving within 24–48 hours
- Expected with any SC peptide. Not compound-specific
- Headache
- 6–8%
- 7–9%
- No dose-relationship observed; incidence overlaps placebo range entirely
- Statistically indistinguishable from baseline
- Gastrointestinal symptoms
- 5–9%
- 6–10%
- Nausea, mild diarrhea, or bloating reported in fewer than 1 in 10 subjects across trials
- No evidence of GI toxicity or chronic effect
- Fatigue
- 4–6%
- 3–5%
- Single trial (diabetes neuropathy) reported slightly elevated fatigue rates at 8mg dosing
- Minimal clinical significance. Overlaps placebo
- Liver enzyme elevation
- <2%
- <1%
- Transient ALT elevation (1.5–2× ULN) in 1 subject, normalized without intervention
- Isolated finding. No hepatotoxicity pattern
- Serious adverse events
- 0%
- No SAEs attributable to ARA-290 across all controlled trials totaling 150+ subjects
- Clean safety signal through 28 weeks